Evidence map›Paper›PMID 40035977›Full record

Observational studyClinical and experimental nephrology2025

Comparison of seroconversion rates after hepatitis B vaccination in patients with advanced chronic kidney disease and those receiving maintenance hemodialysis.

Tomoyuki Fujikura, Shinsuke Isobe, Shigeru Oikawa, Sayaka Ishigaki, Naoko Katahashi, Takamasa Iwakura, Naro Ohashi, Akihiko Kato, Hideo Yasuda

Abstract readObservational StudyComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tomoyuki FujikuraInternal Medicine 1, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan. tfuji@hama-med.ac.jp.ORCID http://orcid.org/0000-0001-8143-8845
Shinsuke IsobeInternal Medicine 1, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Shigeru OikawaSanarudai Asahi Clinic, Hamamatsu, Shizuoka, Japan.
Sayaka IshigakiBlood Purification Unit, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Naoko KatahashiPostgraduate Clinical Education Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Takamasa IwakuraInternal Medicine 1, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Naro OhashiPostgraduate Clinical Education Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Akihiko KatoBlood Purification Unit, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hideo YasudaInternal Medicine 1, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients receiving dialysis are at an increased risk of hepatitis B virus (HBV) infection due to a compromised immune system. While HBV vaccination is recommended, the response rate to the standard vaccination regimen (3 doses of 10 µg HBV vaccine) among patients with chronic kidney disease (CKD) or receiving hemodialysis in Japan is unclear. This study evaluated the seroconversion rate, optimal timing, and CKD stage in patients receiving HBV vaccination.

methodsIn this prospective, observational study conducted from May 2021 to July 2024, patients with advanced CKD not on dialysis and those receiving maintenance hemodialysis at two centers in Japan received 3 doses of 10 µg HBV vaccine at 0, 1, and 6 months. The primary outcome was the seroconversion rate, defined as anti-HBs antibody levels of ≥10 IU/mL, measured 1-3 months after the third dose.

resultsOverall, 113 participants (63 with non-dialysis CKD and 50 with hemodialysis CKD) were included. The seroconversion rates were 64.3% in non-dialysis patients and 54.2% in patients on hemodialysis, with no significant difference (OR = 0.62, 95% CI 0.28-1.38). Multivariate analysis adjusting for covariates showed no significant difference (OR = 0.74, 95% CI 0.29-1.91), and sensitivity analysis confirmed this finding.

conclusionsThe seroconversion rate of the standard HBV vaccination (3×10 µg) was not significantly different from those in non-dialysis patients with CKD. More effective vaccination strategies such as higher doses, third-generation vaccines, or vaccination at an earlier CKD stage are required to improve HBV protection in this population.

Indexed as

Hepatitis BHepatitis B AntibodiesHepatitis B VaccinesRenal DialysisRenal Insufficiency, ChronicSeroconversionAdultAgedFemaleHumansJapanMaleMiddle AgedProspective StudiesTime FactorsVaccinationHepatitis B AntibodiesHepatitis B VaccinesChronic kidney diseaseHepatitis B virusSeroconversion rateVaccination

Identifiers

PMID40035977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.